FinGraph AI values Eli Lilly and Company with a deterministic 3-stage discounted cash flow (DCF) model built from LLY's SEC 10-K/10-Q filings and live market data — then cross-checks it against peer multiples, forensic-accounting scores and a reverse-DCF. Run the full report in under a minute.
Run the live LLY report →A 3-stage unlevered DCF with a CAPM/WACC build-up, compared directly to LLY's market price so you can see the premium or discount to the baseline.
The growth rate the market is currently pricing into Eli Lilly and Company, measured against its real historical performance.
Altman Z (distress), Piotroski F (fundamental strength) and Beneish M (earnings-manipulation) scores from the filings.
Eli Lilly and Company benchmarked on P/E, EV/EBITDA, P/S and margins against a live comparable-company set.
Eli Lilly and Company (NYSE: LLY) is covered in FinGraph AI's Healthcare universe. Every figure in the report traces to LLY's SEC EDGAR filings and live market data — there are no hand-entered numbers, and the DCF is deterministic rather than LLM-estimated. This page is informational and updates when you run the live report.
Value LLY now →Informational research only — not investment advice, and not a recommendation to buy or sell any security. FinGraph AI is not a registered investment adviser. Figures derive from SEC EDGAR filings and market data and may differ from other sources.